FinancialBuzz.com’s latest The Buzz Show: Palisade Bio, Inc. Announces FDA Fast Track Designation for its investigational drug LB1148”
Palisade Bio, Inc. (NASDAQ: PALI) surged over 25% in premarket trading after the company announced an FDA Fast Track Designation for the investigational drug LB1148.
LB1148 has the potential to be the first oral treatment to reduce adhesions following abdominal or pelvic surgery, and was previously granted Fast Track Designation for the treatment of postoperative GI dysfunction associated with gut hypoperfusion injury in pediatric patients who have undergone congenital heart disease repair surgery.
Palisade Bio is a late-stage biopharma company advancing therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio’s innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery. Positive data from Phase 2 trials of LB1148 demonstrated safety and tolerability as well as a statistically significant improvement in return to bowel function and decrease in length of stay in ICU and hospital compared to placebo. Palisade Bio believes that its investigational therapies have the potential to address the myriad health conditions and complications associated with chronic disruption of the gastrointestinal epithelial barrier.
For more information, please visit: Palisade Bio, Inc.
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.